- Published in leading peer-reviewed journal Nature Reviews Drug Discovery
- The review results from a successful collaboration with international research group at the University of Cambridge
- Demonstrates the unique capability of Sosei Heptares' platform to enable peptide, as well as small molecule, lead generation against disease-relevant GPCRs – providing multiple partnering opportunities
TOKYO and LONDON, March 20, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces that a review article entitled 'Advances in Therapeutic Peptides Targeting G Protein-coupled Receptors' (Davenport et al. see below) has been published by Nature Reviews Drug Discovery, a prestigious and highly influential peer-reviewed journal. The article has resulted from a successful collaboration between Sosei Heptares and a leading international research group at the University of Cambridge led by Professor Anthony Davenport.
In the article, the authors systematically review the development of peptide-based drugs targeting G protein-coupled receptors (GPCRs) and the still significant opportunities that exist to apply unique insights from 3D GPCR structures to generate new and improved peptide therapeutics. Nearly 50 GPCR peptide drugs have been approved to date, most of them for metabolic disease or oncology indications, and more than 10 potentially first-in-class peptide therapeutics are in the pipeline.
Professor Davenport, from the Department of Experimental Medicine and Immunotherapeutics at the University of Cambridge, commented: "Peptide therapeutics have been around for about 100 years and are now undergoing a renaissance with revolutionary strategies being employed to improve their attributes as effective drugs (pharmacodynamics and pharmacokinetics). Excitingly, there are still another 50 or so 'orphan' GPCRs, many linked with diseases, for which there is no approved drug and these remain to be exploited clinically."
The article focuses on the new discovery strategies that leverage cutting-edge structure-based technologies, including Sosei Heptares' unique StaR® platform and cryo-EM, to generate novel and selective peptides with precisely designed activities and improved drug-like (pharmacokinetic and pharmacodynamic) properties. Such peptides include agonists, antagonists, as well as peptides designed to activate specific downstream signalling pathways (biased ligands), and dual agonists that activate two different GPCRs.
The generation of novel, precisely designed peptide leads against disease-relevant GPCRs provides multiple partnering opportunities for Sosei Heptares.
Miles Congreve, Chief Scientific Officer of Sosei Heptares, said: "Sosei Heptares is uniquely placed to apply its technology and expertise to the generation of peptide-based drugs against GPCRs. This is a rapidly expanding field with multiple opportunities, which have been highlighted in this high-quality, comprehensive review. While our prime focus is on the discovery of small molecule leads, our StaR® platform and structure-based design expertise has already proved its capability to generate and optimize new peptide leads against target GPCRs. This expanded reach of our technology into peptide drugs allows us to develop further potential products for which we will look to generate value from via proactive targeting of appropriate partners."
Davenport, A.P. et al. Advances in therapeutic peptides targeting G protein- coupled receptors. Nature Rev. Drug Disc. (2020) https://www.nature.com/articles/s41573-020-0062-z
Davenport Laboratory, Experimental Medicine and Immunotherapeutics, University of Cambridge.
About Sosei Heptares
We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications.
We have established partnerships with some of the world's leading pharmaceutical companies, including Allergan, AstraZeneca, Daiichi-Sankyo, Genentech (Roche), Novartis, Pfizer and Takeda; and with innovative biotechnology companies, including Kymab, MorphoSys and PeptiDream. Sosei Heptares is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK.
"Sosei Heptares" is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are Trade Marks of Sosei Group companies.
For more information, please visit https://www.soseiheptares.com/
This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Shinichiro Nishishita – VP Investor Relations
Candelle Chong – VP Corporate Strategy and Communications
Citigate Dewe Rogerson
Yas Fukuda – Japanese Media
Mark Swallow, David Dible – International Media
SOURCE Sosei Heptares